Bryce Chackerian

This paper develops a VLP-based immunogen, MS2.87-97, that elicits anti-Myostatin antibodies, increases muscle mass and strength, and reduces adiposity in mice.

This study compares IgG antibody titers in blood and dermal interstitial fluid after VLP-based vaccine immunization, finding similar titers and durability in both.

This study develops heat-stabilized dissolvable microneedles containing a novel VLP vaccine, showing robust immunogenicity and stability under extreme storage conditions.

This study evaluates virus-like particle vaccines targeting a specific CSP epitope, showing that structural context and adjuvant combinations enhance antibody responses and sterilizing immunity against malaria.

This study shows that two doses of Qβ virus-like particle-based vaccines generate protective antibodies against heroin and fentanyl in animal models.

The paper shows that pathological tau activates NF-κB in microglia and that a pT181-Qβ vaccine reduces NF-κB activity in tauopathy mice.

This study develops a TRIO VLP vaccine targeting Anopheles mosquito salivary protein to enhance immunity against Plasmodium, showing strong antibody responses but limited protective efficacy in a malaria challenge model.

This study compares two VLP-based vaccines targeting different pTau epitopes, finding that the PHF1 vaccine reduces tau pathology and restores cognition better than the AT8 vaccine in a mouse model.